IP Library Granted Patent US 11,149,297
Granted Patent B2
US 11,149,297 · App. 15/866,840 · Granted Oct 19, 2021

Methods for depleting RNA from nucleic acid samples

Inventors: Dominick Sinicropi (Woodside, CA); John Morlan (Foster City, CA)
Assignee: Genomic Health, Inc.
C12Q1/6806C12N15/1003C12Q1/6848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,149,297
App. No.
15/866,840
Granted
Oct 19, 2021
Kind
B2
Abstract

The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.

Claims (26)

1. A method of depleting a target RNA molecule from a fixed, paraffin-embedded (FPET) sample, comprising:

a) contacting nucleic acid obtained from the FPET sample with a multiplicity of DNA probes comprising a plurality of DNA oligonucleotides complementary to a target RNA molecule, wherein the plurality of DNA oligonucleotides specifically hybridizes to at least 80% of the entire full length sequence or to the entire full length sequence of the target RNA molecule and forms a DNA-RNA hybrid, wherein the multiplicity of probes includes at least two probes complementary to sequences that overlap one another; and

b) contacting the sample with a ribonuclease (RNase) that specifically recognizes a DNA-RNA hybrid;

wherein the RNase degrades the RNA in the DNA-RNA hybrid formed from the target RNA molecule and the plurality of DNA oligonucleotides.

2. The method of claim 1 , wherein the RNase is RNase H.

3. The method of claim 2 , wherein the RNAse H is a thermostable RNAse H.

4. The method of claim 1 , wherein the target RNA molecule is a ribosomal RNA (rRNA).

5. The method of claim 4 , wherein the rRNA is 18S or 28S, or both.

6. The method of claim 4 , wherein the rRNA is 12S or 16S, or both.

7. The method of claim 1 , wherein the DNA oligonucleotides comprise from 60 to 80 bases.

8. The method of claim 1 , wherein the nucleic acid obtained from the FPET sample comprises total RNA.

9. The method of claim 1 , wherein the nucleic acid obtained from the FPET sample comprises amplified RNA.

10. The method of claim 1 , further comprising the step of contacting the sample with a DNase, wherein the DNase degrades the DNA probe.

11. The method of claim 10 , wherein the DNase is DNase I.

12. The method of claim 1 , wherein the target RNA molecules comprise less than 10% of all RNA present in the sample after degradation with RNase.

13. The method of claim 1 , wherein the FPET sample is from a tumor.

14. The method of claim 13 , wherein the tumor is a cancer.

15. The method of claim 14 , wherein the cancer is selected from breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.

16. The method of claim 1 , wherein the nucleic acid obtained from the FPET sample comprises fragmented RNA.

17. A method of preparing cDNA comprising:

a) obtaining a nucleic acid sample;

b) contacting the nucleic acid sample with a multiplicity of DNA probes comprising a plurality of DNA oligonucleotides complementary to a target RNA molecule, wherein the plurality of DNA oligonucleotides specifically hybridizes to at least 80% of the entire full length sequence or to the entire full length sequence of the target RNA molecule and forms a DNA-RNA hybrid, wherein the multiplicity of probes includes at least two probes complementary to sequences that overlap one another;

c) contacting the nucleic acid sample with a ribonuclease (RNase) that specifically recognizes a DNA-RNA hybrid; wherein the RNase degrades the RNA in the DNA-RNA hybrid formed from the target RNA molecule and the plurality of DNA oligonucleotides; and

d) preparing cDNA from the nucleic acid sample.

18. The method of claim 17 , wherein the nucleic acid sample is obtained from a FPET sample.

19. The method of claim 18 , wherein the nucleic acid sample comprises fragmented RNA.

Assignments (2)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0380) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: GENOMIC HEALTH, INC.
Reel/Frame 075294/0821 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: GENOMIC HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0380 →
Continuity (4)
Division 14644455 · Mar 11, 2015
Division 12940981 · Nov 5, 2010
Provisional Application 61259934 · Nov 10, 2009
Related Publication 20180208968A1 · Jul 26, 2018